New Singapore Center For WuXi As It Looks Beyond China
'Dual Sourcing' Marches On
The Southeast Asian island nation could emerge a winner as China and Hong Kong continue to show few signs of easing their strict COVID policies and companies look to diversify their global supply chains.
You may also be interested in...
While new legislation has pushed prescription drug pricing high up the political agenda for US lawmakers, the issue has also come into the spotlight again for Chinese regulators, which have just launched new investigations into two officials. While the two countries are taking drastically different routes to tackling pricing, the developments show compliance risks remain high in China.
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.
Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.